Home > Food & Beverages > Proteins > Animal-Based Proteins > Human Milk Oligosaccharides (HMO) Market
Human Milk Oligosaccharides Market size was valued at USD 200 million in 2022 and is estimated to grow at over 22.5% CAGR from 2023 to 2032. Human milk oligosaccharides are present in breast milk and play essential roles in infant gut health, immune system development, and protection against pathogens. Infant formula manufacturers are incorporating HMOs in their products to mimic the benefits of human breast milk.
HMOs act as prebiotics, promoting the growth of beneficial gut bacteria and supporting a healthy gut microbiome. Consumers are increasingly aware of the importance of gut health and seek products with prebiotic properties. HMOs have been associated with immune system support and reduced risk of infections in infants. The demand for immune-enhancing ingredients has led to interest in HMOs as functional food ingredients.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Human Milk Oligosaccharides Market Size in 2022: | USD 200 Million |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 22.5% |
2032 Value Projection: | USD 1.51 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 120 |
Tables, Charts & Figures: | 137 |
Segments covered: | Concentration, Application, Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
The production of HMOs, particularly those obtained through microbial fermentation or plant-based sources, can be expensive. The cost of production is a significant challenge that can limit the widespread adoption of HMOs in various applications, including infant formula and functional foods. The use of HMOs in food and dietary supplements is subject to regulatory approvals in different countries. Human milk-derived HMOs are in high demand, but their availability is limited to the production of human breast milk.